within Pharmacolibrary.Drugs.ATC.C;

model C01CA06_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.389,
    Cl             = 0.0004733333333333333,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.34,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0055000000000000005,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C01CA06_1</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Phenylephrine is a selective alpha-1 adrenergic receptor agonist used primarily as a decongestant, to increase blood pressure in hypotensive states such as shock, and as a mydriatic agent for ophthalmic procedures. It is approved for use via various routes including oral, intravenous, and topical administration. Injectable phenylephrine is used in hospital settings for acute hypotension.</p><h4>Pharmacokinetics</h4><p>Oral administration, healthy fasting adults, single dose. Both males and females (age 18–55 years)</p><h4>References</h4><ol><li><p>Gelotte, CK, et al., &amp; Zimmerman, BA (2023). Single-Dose Pharmacokinetics and Metabolism of the Oral Decongestant Phenylephrine HCl in Children and Adolescents. <i>Pulmonary therapy</i> 9(1) 139–150. DOI:<a href=&quot;https://doi.org/10.1007/s41030-022-00206-8&quot;>10.1007/s41030-022-00206-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36480111/&quot;>https://pubmed.ncbi.nlm.nih.gov/36480111</a></p></li><li><p>Kanfer, I, et al., &amp; Vuma, V (1993). Pharmacokinetics of oral decongestants. <i>Pharmacotherapy</i> 13(6 Pt 2) 116S–146S. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7507589/&quot;>https://pubmed.ncbi.nlm.nih.gov/7507589</a></p></li><li><p>Gelotte, CK, &amp; Zimmerman, BA (2015). Pharmacokinetics, safety, and cardiovascular tolerability of phenylephrine HCl 10, 20, and 30 mg after a single oral administration in healthy volunteers. <i>Clinical drug investigation</i> 35(9) 547–558. DOI:<a href=&quot;https://doi.org/10.1007/s40261-015-0311-9&quot;>10.1007/s40261-015-0311-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26267590/&quot;>https://pubmed.ncbi.nlm.nih.gov/26267590</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C01CA06_1;
